Podcast

Managing Neurologic Disease in the Era of COVID-19: Focus on Botulinum Toxin

Launch Date
06/11/2020
Credit Amount
0.00 Expired
Credit Expires
06/11/2021

Faculty

David M. Simpson, MD, FAAN
Professor of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY
Director, Clinical Neurophysiology and Neuromuscular Division, Icahn School of Medicine at Mount Sinai, New York, NY
David M. Simpson, MD, FAAN

David M. Simpson, MD, is Professor of Neurology at Icahn School of Medicine at Mount Sinai in New York, New York. He is also Director of the Clinical Neurophysiology Laboratories and Neuromuscular Division.

Dr. Simpson received his medical degree from State University of New York (SUNY) at Buffalo School of Medicine. He completed an internship in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University in Cleveland, Ohio, and a residency in Neurology at Cornell University Medical Center in New York. He had a fellowship in Clinical Neurophysiology at Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts.

Dr. Simpson is author of over 246 original peer-reviewed publications, 96 book chapters and, has edited 3 books, and serves on numerous editorial boards. He has been the principal investigator for numerous studies, including the treatment of neuropathic pain in patients with peripheral neuropathy, neurological complications of HIV/AIDS and treatment of spasticity, limb dystonia and tremor with botulinum toxin. He is Chair of the American Academy of Neurology’s Subcommittee charged with generating evidence-based guidelines for the use of botulinum toxin. Dr. Simpson is a member of the American Neurological Association and the American Pain Society, Fellow of the American Academy of Neurology and the American Academy of Neuromuscular and Electrodiagnostic Medicine and President-Elect of the International Neurotoxin Association. He has received the Mitchell B Max Award for Neuropathic Pain from the American Academy of Neurology in 2018, granted for outstanding achievements in the field of neuropathic pain.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

In response to the spread of COVID-19, it is important to develop a plan for effective and timely patient triage. Especially for patients with spasticity, this initial assessment must factor in quality of life (QoL). It is also critical to provide the appropriate level of care to all patients, irrespective of COVID-19 infection status. Along with assessing QoL, clinicians must ensure medication adherence and stay connected with their patients to address concerns and provide valuable educational tools.

This CMEOCast podcast episode focuses on putting the patient at the heart of all care and specific interventions for the treatment of spastic paresis during the COVID-19 pandemic.

Learning Objectives

At the end of this CME/CE activity, participants should be able to optimize care of patients with neurologic disorders during the COVID-19 era.

The following learning objectives pertain only to those requesting CNE or CPE credit describe how to optimize care of patients with neurologic disorders during the COVID-19 era.

Financial Support

Supported by an educational grant from Allergan.

Target Audience

Physicians, PAs, nurse practitioners, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-20-101-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Simpson reports that he receives research/grants from Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc. He is on the advisory committee for Allergan; Ipsen Biopharmaceuticals, Inc; Merz Pharma; and Revance Therapeutics, Inc. He is a consultant for Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc. He is on the speakers bureau for Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc.

  • Evan Luberger (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-101-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

PD-021-061120-03

Managing Neurologic Disease in the Era of COVID-19: Focus on Botulinum Toxin
Event Date: 06/11/2020